Submitted by Anonymous (not verified) on 18 August 2026 - 13:42
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 16, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 16, Status: Authorised